Launch of new multi-center study investigating resorbable drug-eluting microspheres safety and efficacy | https://www.terumo-europe.com/en-emea/news/launch-of-new-multi-center-study-investigating-resorbable-drug-eluting-microspheres-safety-and-efficacy | Launch of new multi-center study investigating resorbable drug-eluting microspheres safety and efficacy | | 3/10/2024 11:00:00 PM | <p><span lang="EN-GB" style="font-family:"segoe ui", sans-serif;"></span><span lang="EN-GB" style="font-family:"segoe ui", sans-serif;">Terumo Europe N.V. announces the launch of the BIOPEARL-ONE study, a new multi-center post market clinical trial: BioPearl<sup>TM</sup> microspheres are loaded with doxorubicin to treat patients with unresectable hepatocellular carcinoma (HCC). A prospective, single arm, multi-centre post-market follow-up study is intended to assess the safety and efficacy of BioPearl<sup>TM</sup> microspheres loaded with doxorubicin in the treatment of patients with unresectable HCC. </span><br></p> |
Terumo expands global presence with new subsidiary in South-Africa | https://www.terumo-europe.com/en-emea/news/terumo-expands-global-presence-with-new-subsidiary-in-south-africa | Terumo expands global presence with new subsidiary in South-Africa | | 11/29/2023 11:00:00 PM | <p>Terumo Corporation (TSE: 4543) today announced the establishment of Terumo South Africa (Pty) Ltd. (Terumo South Africa), its newest subsidiary in South-Africa. This strategic move represents a significant milestone in the company’s continued commitment to expanding its global footprint and strengthening its presence in key growing markets.<br></p> |
ANGIO-SEAL™ VIP & FEMOSEAL™ VASCULAR CLOSURE DEVICES SECURED CE CERTIFICATE UNDER THE NEW MEDICAL DEVICE REGULATION | https://www.terumo-europe.com/en-emea/news/angio-seal™-vip-femoseal™-vascular-closure-devices-secured-ce-certificate-under-the-new-medical-device-regulation | ANGIO-SEAL™ VIP & FEMOSEAL™ VASCULAR CLOSURE DEVICES SECURED CE CERTIFICATE UNDER THE NEW MEDICAL DEVICE REGULATION | | 10/3/2023 10:00:00 PM | <p>Terumo (TSE: 4543) is proud to announce that both of our Vascular Closure Devices, Angio-Seal™ VIP & Femoseal™, received the EU MDR certifications.<br></p> |
Terumo Group Associates Celebrate Terumo Patient’s Day 2023 | https://www.terumo-europe.com/en-emea/terumo-group-associates-celebrate-terumo-patient’s-day-2023 | Terumo Group Associates Celebrate Terumo Patient’s Day 2023 | | 9/14/2023 10:00:00 PM | <p>Terumo Corporation (TSE: 4543) today held “Terumo Patient’s Day 2023” to connect with Terumo’s Group Mission of “Contributing to Society through Healthcare”, and for each associate to reconfirm their day-to-day contribution at work ultimately leads to the well-being of patients.<br></p> |
Terumo to Construct a New Manufacturing Facility at its Kofu Factory for the Medical Care Solutions Company | https://www.terumo-europe.com/en-emea/news/terumo-to-construct-a-new-manufacturing-facility-at-its-kofu-factory-for-the-medical-care-solutions-company | Terumo to Construct a New Manufacturing Facility at its Kofu Factory for the Medical Care Solutions Company | | 5/14/2023 10:00:00 PM | <p>52.2 Billion JPY Capital Investment to Strengthen the Production Capability to Meet the Growing Global Demands<br></p> |
Ultimaster Nagomi™ MDR certification and launch of large-scale post-market study investigating the new coronary stent system in complex PCI | https://www.terumo-europe.com/en-emea/news/ultimaster-nagomi™-mdr-certification-and-launch-of-large-scale-post-market-study-investigating-the-new-coronary-stent-syste | Ultimaster Nagomi™ MDR certification and launch of large-scale post-market study investigating the new coronary stent system in complex PCI | | 4/25/2023 10:00:00 PM | <p></p>First patient enrolled in the NAGOMI COMPLEX PMCF study <br> |